STX-478

CAS No. 2883540-92-7

STX-478( —— )

Catalog No. M37154 CAS No. 2883540-92-7

STX-478 is an orally active and selective PI3Kα inhibitor that penetrates the blood-brain barrier and has anticancer activity to inhibit tumor growth.STX-478 is indicated for the study of breast cancer and other cancers.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 514 Get Quote
5MG 816 Get Quote
10MG 1292 Get Quote
25MG 2548 Get Quote
50MG 4076 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    STX-478
  • Note
    Research use only, not for human use.
  • Brief Description
    STX-478 is an orally active and selective PI3Kα inhibitor that penetrates the blood-brain barrier and has anticancer activity to inhibit tumor growth.STX-478 is indicated for the study of breast cancer and other cancers.
  • Description
    STX-478 (compound 80) is an oral CNS-penetrant allosteric mutant-selective PI3Kα inhibitor. STX-478 shows robust and durable tumor regression and can be used in cancer research.
  • In Vitro
    Immunofluorescence Cell Line:MCF10A cells Concentration:0-10,000 nM Incubation Time:1 h Result:Targeted the MCF10A cells (with the H1047R kinase domain mutation).
  • In Vivo
    Animal Model:Female BALB/c nude mice (CAL-33 xenograft model).Dosage:30, 100 mg/kg Administration:Oral administration Result:Showed a dose-dependent reduction in tumor volume.
  • Synonyms
    ——
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    PI3K
  • Recptor
    PI3K
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2883540-92-7
  • Formula Weight
    401.29
  • Molecular Formula
    C16H12F5N5O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 250 mg/mL (622.99 mM; Ultrasonic )
  • SMILES
    [C@H](NC(NC=1C=NC(N)=NC1)=O)(C(F)(F)F)C2=C(C)C=3C(O2)=C(F)C=C(F)C3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. JR David St Jean, et al. Urea derivatives which can be used to treat cancer. Patent WO2022265993A1.
molnova catalog
related products
  • SN-32976

    SN-32976 is a novel, potent and selective class I PI3K and mTOR inhibitor.

  • IHMT-PI3Kδ-372 S-iso...

    IHMT-PI3Kδ-372 S-isomer is a potent and selective PI3Kδ inhibitor with an IC50 of 14 nM. IHMT-PI3Kδ-372 S-isomer shows high selectivity over other class I PI3Ks (56~83 fold) and other protein kinases.

  • GSK1016790A

    GSK1016790A (GSK101) is a novel, potent activator of TRPV4 (transient receptor potential vanilloid 4) with EC50 of 34 nM in choroid plexus epithelial cells.